This logic has manifested in the newly released guidance to companies interested in pursuing a broad listing for cancer immunotherapies. An expectation of no net cost. Patients, you waited nine years for this, and it was granted on the basis that your treatment cost the government nothing. That is what your life is worth.
Watching this system has become like cheering for an elephant on a unicycle
June 24, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Australian company secures European approval for rare disease treatment
August 26, 2026 - - Latest News -
Australia cannot deliver meaningful change until the levers of power are rebalanced
August 26, 2026 - - Latest News -
Insurers warn cut could hit Australians most likely to need cancer care
August 25, 2026 - - Latest News -
Australian study finds maternal RSV vaccination offers strong protection for infants
August 25, 2026 - - Latest News -
Acrux brings experienced clinical leader aboard to advance testosterone program
August 24, 2026 - - Australian Biotech -
Avecho moves to deepen global partnering push as CBD insomnia program advances
August 24, 2026 - - Australian Biotech -
July recommendations across oncology, rare disease and chronic care
August 24, 2026 - - Latest News

